Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events.

Journal of medical systems - 1 Aug 2010

Ohashi Wataru, Tanaka Hiroshi

Abstract excerpt

Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost-benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet. The purpose of this study is to investigate advantages obtained by introducing PGx in clinical trials. Particularly, taking Warfarin as an example, we investigate benefits of Enrichment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Clinical Trials as Topic
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Mixed Function Oxygenases

Share to Precision Medicine

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 20703925
DOI: 10.1007/s10916-009-9284-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events.PMID 20703925Read ↗

Pharmacogenomics in early-phase clinical development.Semantic proximity Read ↗

Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity Read ↗

In Pursuit of Greater Reproducibility and Credibility of Early Clinical Biomarker ResearchSemantic proximity Read ↗

Pharmacoeconomic evaluation of warfarin pharmacogenomics.Semantic proximity Read ↗

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.Semantic proximity Read ↗

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesSemantic proximity Read ↗

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read ↗

Drug researchers take on 'superbugs'.Semantic proximity Read ↗

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read ↗

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.